Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IPLEX vs REGRANEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes chemotaxis and proliferation of fibroblasts, smooth muscle cells, and other cells involved in wound healing, and stimulates granulation tissue formation.
FDA: Treatment of growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome, GH gene deletion, GH receptor defects) or with neutralizing antibodies to GH.,Off-label: Treatment of insulin-like growth factor-1 deficiency in adults; investigational in ALS and other neurodegenerative disorders.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply.,Off-label: pressure ulcers, venous stasis ulcers, other chronic wounds.
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
Apply topically once daily, a thin layer to the full area of the ulcer, using a measured amount of gel based on ulcer length and width in centimeters: (length × width × 0.5) grams.
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Terminal half-life ~30-60 minutes after topical application; prolonged in renal impairment (up to 2-3 hours). Clinical context: Short systemic exposure limits off-target effects.
Mecasermin (IGF-1) is metabolized by proteolytic degradation into amino acids; IGFBP-3 is also proteolytically degraded. No significant cytochrome P450 metabolism.
Metabolized locally; no systemic metabolism expected due to topical administration and minimal absorption. If absorbed, degraded by proteolytic enzymes at the wound site.
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
Primarily renal; minimal biliary/fecal. Becaplermin is cleared renally (>90% as metabolites) with <2% excreted unchanged. Fecal elimination accounts for <10%.
Approximately 90% bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, and a minor fraction to albumin.
~25% bound to plasma proteins (primarily albumin).
Vd approximately 0.25-0.30 L/kg, indicating distribution primarily to extracellular fluid and well-perfused tissues.
Vd ~12 L (~0.17 L/kg assuming 70 kg), indicating limited extravascular distribution due to molecular size.
Subcutaneous: Approximately 80-100%.
Topical: Negligible systemic bioavailability (<1% of applied dose absorbed; increased with large wounds or impaired skin barrier).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30–50 m L/min), reduce dose by 25%; monitor IGF-I closely.
No dose adjustment required for renal impairment.
Not studied in hepatic impairment; use with caution in Child-Pugh B or C; consider dose reduction based on clinical response and IGF-I monitoring.
No dose adjustment required for hepatic impairment.
0.5-2 mg/kg subcutaneously once daily, titrated to achieve age-appropriate IGF-I levels.
Safety and efficacy in pediatric patients have not been established; use not recommended.
No specific dose adjustment; initiate at lower end of dosing range (0.5 mg/kg/day) due to potential for decreased renal function and increased sensitivity.
No specific dose adjustment recommended; use with caution due to potential comorbidities and polypharmacy.
Not available (no FDA boxed warning as of current labeling).
Increased risk of mortality secondary to malignancy in patients treated with 3 or more tubes of REGRANEX (becaplermin) Gel. A postmarketing study showed increased mortality from cancer in patients who used three or more tubes of REGRANEX compared to control patients. REGRANEX should only be used when the benefits can be expected to outweigh the risks. REGRANEX is not recommended in patients with known malignancy.
Hypoglycemia (especially in fasted state), intracranial hypertension, slipped capital femoral epiphysis, lymphatic tissue hypertrophy (e.g., tonsillar/adenoid enlargement), allergic reactions, and progression of pre-existing malignancies. Injection site reactions, lipohypertrophy. Risk of hyperglycemia if used in patients with diabetes. Monitor blood glucose, fundoscopy for papilledema, and for signs of hip/knee pain.
Application to wounds with active malignancy may promote tumor growth. Application to wounds with infection or necrotic tissue should be discontinued until infection is controlled or necrotic tissue debrided. Potential for immunogenicity.
Hypersensitivity to mecasermin rinfabate or any component; active or suspected neoplasia; epiphyseal closure (skeletal maturity); children with closed epiphyses (except if indicated for severe IGF-1 deficiency with open epiphyses).
Known hypersensitivity to becaplermin or any product component. Application to wounds with known neoplasms or active malignancy. Use on wounds closed by primary intention.
No specific food interactions reported. However, to minimize hypoglycemia risk, IPLEX should be administered immediately after a meal or snack. Avoid prolonged fasting. Alcohol use may increase hypoglycemia risk; avoid or limit alcohol consumption.
No known food interactions. Regranex is applied topically and has minimal systemic absorption.
IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of IGF-1 during organogenesis resulted in fetal growth retardation and increased skeletal abnormalities at doses similar to human exposure. Due to its growth-promoting effects, potential for teratogenicity, and interference with normal fetal development, IPLEX is contraindicated during pregnancy. First trimester: Risk of skeletal and growth abnormalities. Second and third trimesters: continued risk of abnormal fetal growth and development, including organ overgrowth or underdevelopment. Use only if maternal benefits outweigh potential fetal risks; however, generally avoided.
No adequate and well-controlled studies in pregnant women. Animal studies at doses 25-100 times human exposure show no fetal harm. Risk cannot be ruled out; use only if potential benefit justifies potential risk.
It is unknown whether mecasermin rinfabate or its components (IGF-1, IGFBP-3) are excreted in human milk. Due to the potential for serious adverse reactions in the nursing infant, including growth stimulation and hypoglycemia, breast-feeding is not recommended during IPLEX therapy. No M/P ratio is available.
It is not known whether becaplermin is excreted in human milk. M/P ratio unknown. Use caution; consider developmental and health benefits of breastfeeding along with mother's clinical need for REGRANEX.
No specific pharmacokinetic studies of IPLEX in pregnancy are available. The physiological changes of pregnancy (increased plasma volume, altered renal function, increased hepatic metabolism) may affect clearance of mecasermin rinfabate; however, due to its contraindication, dose adjustments during pregnancy are not recommended. If absolutely necessary, use the lowest effective dose and monitor for efficacy and adverse effects. No established dose adjustment guidelines exist.
No pharmacokinetic data in pregnancy. Dosage adjustments are not recommended based on current knowledge; use same dosing as non-pregnant adults.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (rh IGF-1) and its binding protein (rh IGFBP-3). It is indicated for growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome) or with GH gene deletion who have developed neutralizing antibodies to GH. Administer subcutaneously; dose is based on IGF-1 levels. Monitor for hypoglycemia, especially after injection; patients should eat shortly after dosing. Do not use in patients with closed epiphyses or active neoplasia. May cause lymphoproliferative disorders; monitor for splenomegaly, lymphadenopathy.
Regranex (becaplermin) is a recombinant platelet-derived growth factor (PDGF) gel indicated for diabetic neuropathic ulcers extending into subcutaneous tissue or deeper. Ensure ulcer is free of infection, necrotic tissue, and has adequate blood supply before initiating therapy. Apply a thin layer once daily, and recalibrate gel amount based on ulcer dimensions (length x width x 0.5 for cm to grams). Do not use on wounds with exposed bone, tendon, or joint. Monitor for increased risk of malignancy; contraindicated in patients with active malignancies. The gel is for single-patient use only; discard tube 30 days after opening.
Inject IPLEX within 20 minutes after a meal or snack to prevent hypoglycemia.,Rotate injection sites (abdomen, thigh, upper arm) to avoid lipohypertrophy.,Report symptoms of hypoglycemia (shakiness, sweating, confusion) or increased growth velocity.,Keep a log of blood glucose levels if advised by your doctor.,Store IPLEX in the refrigerator (2-8°C); do not freeze. Protect from light.,Do not share needles or pens; dispose of used needles in a sharps container.,Continue regular follow-up appointments for growth monitoring and blood tests.
Wash hands before and after applying Regranex.,Clean the ulcer gently with saline or water before each application.,Apply a thin layer of gel (about 1/16 inch) to the entire ulcer area once daily.,Cover the ulcer with a saline-moistened gauze dressing after applying gel.,Do not use more than the prescribed amount or frequency.,Store Regranex in the refrigerator; do not freeze.,Discard any unused gel in the tube 30 days after first opening.,Report any signs of infection (increased pain, redness, swelling, foul odor) or new skin changes around the wound.,You may need to have your wound measured weekly to adjust the gel amount.,Avoid applying other creams, ointments, or lotions to the same area.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IPLEX vs REGRANEX, answered by our medical review team.
IPLEX is a Growth Factor that works by IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.. REGRANEX is a Topical Growth Factor (Platelet-Derived) that works by Recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes chemotaxis and proliferation of fibroblasts, smooth muscle cells, and other cells involved in wound healing, and stimulates granulation tissue formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IPLEX and REGRANEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IPLEX is: 0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.. The standard adult dose of REGRANEX is: Apply topically once daily, a thin layer to the full area of the ulcer, using a measured amount of gel based on ulcer length and width in centimeters: (length × width × 0.5) grams.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IPLEX and REGRANEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IPLEX is classified as Category C. IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in . REGRANEX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies at doses 25-100 times human exposure show no fetal harm. Risk cannot be ruled out; use only if potential b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.